Cyclosporine (CSP) and short course methotrexate (MTX) have been the gold standard for GVHD prophylaxis for decades. Problems associated with MTX include increased time to hematopoietic engraftment, mucositis, and other organ toxicities. The combination of CSP with mycophenolate mofetil (MMF) has been used successfully for the prevention of graft rejection and GVHD in nonmyeloablative transplantation. We performed a prospective randomized trial comparing CSP and MTX with CSP and MMF in myeloablative (busulfan based) allogeneic 6/6 matched sibling bone marrow transplantation (BMT). The group receiving MMF (n ¼ 21) had significantly less severe mucositis than did the group receiving MTX (n ¼ 19) (21 vs 65%, P ¼ 0.008). Median time to neutrophil engraftment was more rapid in the MMF group (11 vs 18 days, Po0.001). The incidence of acute GVHD, as well as 100 day survival, was similar for both groups. The reduced toxicity of the CSP and MMF arm resulted in premature study closure. We conclude that a GVHD prophylaxis regimen of CSP and MMF after a myeloablative allogeneic preparative regimen is associated with faster hematopoietic engraftment, decreased incidence of mucositis, similar incidence of aGVHD, and comparable survival as compared to CSP and MTX.
tion; mycophenolate; methotrexate The combination of cyclosporine (CSP) with short-course methotrexate (MTX) (5-15 mg of MTX given on days 1, 3, 6, and 11) after allogeneic bone marrow transplantation (BMT) has the gold standard for prophylaxis against acute graft-vs-host disease (GVHD) for decades.
1,2 Unfortunately, toxicities from MTX, even with low doses, may be a cause of significant morbidity after myeloablative allogeneic BMT. A common adverse effect of MTX is mucositis, which may be severe and debilitating. Additionally, MTX may result in a delay to neutrophil and platelet engraftment. MTX may also contribute to hepatic toxicity post transplant. Finally, the use of MTX in patients with hepatic or renal insufficiency is a potential clinical concern. The combination of CSP with mycophenolate mofetil (MMF) has been used for GVHD prophylaxis (and to prevent graft failure/rejection) with great success in nonmyeloablative allogeneic transplantation.
2-7 MMF does not cause mucositis and avoids most of the other potential problems associated with MTX. MMF, however, is a potent immunosuppressive agent and theoretically may increase the risk of opportunistic infections. Given the fact that CSP and MMF have been both efficacious and well tolerated in a nonmyeloablative setting, we performed a prospective trial to compare this regimen's efficacy with CSP and MTX for GVHD prophylaxis after myeloablative allogeneic BMT.
Materials and methods

Study design
Eligible patients included those with hematologic malignancy who were appropriate candidates for a myeloablative allogeneic BMT. All patients were required to have a 6/6 HLA matched related donor. All donors were required to undergo a bone marrow harvest. This protocol was reviewed and approved by the Cleveland Clinic Foundation's Institutional Review Board, with informed consent obtained from all patients. Patients were prospectively randomized 1 : 1 to receive either CSP plus MTX or CSP plus MMF for GVHD prophylaxis. All patients received 300 mg/m 2 CSP by continuous infusion intravenous daily from day À1 until hematopoietic engraftment, and thereafter orally attempting to maintain a therapeutic trough level of 200. Patients randomized to MTX received a dose of 5 mg/m 2 intravenously on day þ 1, þ 3, þ 6, and þ 11 after allogeneic BMT. Patients randomized to MMF received 500 mg three times daily either intravenously or orally depending on the patient's ability to tolerate oral medication with the first dose administered on day þ 1 after BMT and continuing until day þ 100. Study end points included the incidence of acute GVHD, severity of mucositis, time to engraftment of neutrophils and platelets, and 100-day survival.
Definitions
Patients were divided into 'good risk' and 'poor risk' based on disease status at the time of transplant. Good risk was defined as any leukemia in complete remission, chronic myelogenous leukemia in chronic phase, chemotherapysensitive follicular lymphoma, aplastic anemia, or chemotherapy sensitive chronic lymphocytic lymphoma. Poor risk was defined as any other disease status, including chemotherapy insensitive malignancies and refractory disease.
Bone marrow transplant preparative regimen and supportive care
The preparative regimen was busulfan and cyclophosphamide (busulfan 16 mg/kg orally, cyclophosphamide 120 mg/kg). All patients received allogeneic bone marrow from donors undergoing a bone marrow harvest. Patients were hospitalized for the delivery of high-dose chemotherapy and discharged after adequate hematological recovery. Platelet or RBC transfusions were routinely administered for a platelet count o15 Â 10 9 /l or hemoglobin o8.5 g/dl, respectively. All blood products were irradiated prior to infusion. Broad-spectrum antibiotics were administered for febrile neutropenic episodes. GCF was given on day þ 5 after allogeneic BMT. Patients who were serologically positive for CMV or who had donors who were serologically positive for CMV received ganciclovir prophylaxis after engraftment until day þ 100, and acyclovir thereafter. All patients received G-CSF 480 mg i.v. starting on day þ 1 until neutrophil engraftment.
All patients received the following prophylactic regimens for oral mucositis: Peridex mouthwash (15 cm 3 ) t.i.d. and either mycostatin mouthwash t.i.d. or mycelex troche q.i.d. Engraftment was defined as follows: neutrophil engraftment was the day to an absolute neutrophil count of 500/ul on two consecutive days; platelet engraftment as the day to achieving a platelet count of 20 000/ul independent of platelet transfusions for 3 consecutive days.
Measurement of mucositis and GVHD
We used the modified OMAS mucositis tool to evaluate mucositis. 8 The OMAS scale evaluates multiple regions of the oral cavity for erythema (none, mild, moderate, severe) and the presence of ulcerations or pseudomembranes. The scale ranges from 0 to 2.0; a score of 0.5 or greater is considered to be severe mucositis. Patients were evaluated for mucositis three times a week from admission to day þ 21. The severity of mucositis for an individual patient was defined as the maximum OMAS score recorded during the first 21 days post transplant. Acute GVHD was monitored weekly while patients were hospitalized for their allogeneic BMT, and at a minimum of weekly for the first 60 days, and a minimum of every 21 days for the first 100 days. Acute GVHD was graded using the NMDP scale for GVHD grading.
Statistical analysis
The primary end points for the study were incidence of acute GVHD and severe mucositis. We hypothesized that MMF would reduce the incidence of severe mucositis while not increasing the incidence of acute GVHD that is seen with MTX. The study was designed as a prospective, randomized study in which 80 patients were to be randomized 1:1 to receive MMF or MTX along with CSP for GVHD prophylaxis. The study was designed to detect an absolute difference of 30% in the incidence of severe mucositis between the two study arms (77% incidence with MTX, 47% with MMF) with 80% power using a two-sided significance level of 5%. No interim analyses were planned. However, due to slower than anticipated accrual, we decided to conduct an interim analysis after the first 40 patients were enrolled. The Lan and DeMets alphaspending function with a Pocock stopping boundary was employed for this interim analysis. Using this approach, a nominal significance level of Po0.03 was needed for the results to be considered statistically significant. The major end points of the study were the incidence of severe mucositis and acute GVHD. The speed of hematopoietic engraftment was a secondary end point. If one arm of this trial resulted in a significantly more favorable result with respect to the incidence of severe mucositis or severe acute GVHD at the time of interim analysis, the study would be terminated. Categorical variables were summarized as frequencies and percentages, and compared between groups using the w 2 test. Continuous variables were summarized as the median and range, and compared between groups using the Wilcoxon rank sum test. Survival, relapse, and relapsefree survival were calculated from the date of transplant. These outcomes were estimated using the Kaplan-Meier method and compared between groups using the log-rank test. All analyses were conducted using SAS s software (SAS Institute, Cary, NC, USA), and all statistical tests were two sided.
Results
In total, 21 patients received MMF and 19 patients received MTX. Patient demographics are shown in Table 1 Figure 1 . In addition, the MMF group had significantly less severe mucositis than the MTX group (21 vs 65%, P ¼ 0.008). More patients in the MTX arm required narcotics to control pain associated with mucositis (94 vs 75%), and took narcotics for more days (15.5 vs 9.5) during the peritransplant period. Additionally, 64% of patients in the MTX arm required TPN during the period of mucositis vs only 19% in the MMF arm.
Engraftment was faster in the MMF group. Median time until neutrophil engraftment was 11 days (range 8-24) with MMF vs 18 days (range 11-28), with MTX (Po0.001). The median time until platelet engraftment was 19 days (range 13-44) in the MMF group vs 23 days (range 14-65) in the MTX group (P ¼ 0.008). The combination of a more rapid engraftment and less severe mucositis leads to a shorter inpatient length of stay for the MMF group (median 27 vs 36 days, Po0.001).
The incidence and severity of acute GVHD was similar in the two groups. The incidence of grade 0-1 acute GVHD was similar in the two arms (52% in the MMF arm and 62% in the MTX arm). The incidence of grade II-IV acute GHVD was 48% in the MMF arm and 37% in the MTX group (P ¼ 0.49). The incidence of chronic GVHD was similar in both groups. For those who survived more than 100 days, the incidence of chronic GVHD was 63% in the MMF group and 64% in the MTX group (P ¼ NS).
Interim analysis of the first 40 patients revealed that the use of CSP and MMF was associated with a reduced severity of mucositis, faster hematopoietic engraftment, similar incidence of acute GVHD events, and comparable survival (which resulted in premature study closure).
There was no significant difference in survival. The 6-month overall survival was 52% for the MMF group and 68% for the MTX group (P ¼ 0.23); 6-month relapse-free survival was 48% (MMF) vs 53% (MTX), P ¼ 0.53. There was no difference in rates of relapse between the two groups (38% MMF vs 47% MTX, P ¼ 0.81, log-rank test). There was no difference in survival between the two groups when analyzing the good and poor risk groups separately.
In this high-risk group of patients, disease relapse was the most common cause of death, accounting for 47% of deaths in the MMF group and 50% of deaths in the MTX group. Other causes of death included acute GVHD (n ¼ 2), chronic GVHD (n ¼ 4), multisystem organ failure (n ¼ 4), and other (n ¼ 3).
The incidence of infections was similar in the two study groups. The incidence of CMV viremia post transplant was 43% in the MMF group and 47% in the MTX group. In toal, 14 patients developed Gram negative bacteremia, seven in each study group. The most common organisms were pseudomonas aeroginosa (n ¼ 4) and klebsiella pneumoniae (n ¼ 3).
Discussion
It is well known that clinical GVHD is associated with a beneficial graft-versus-tumor effect. Unfortunately, excessive GVHD increases the morbidity and mortality associated with allogeneic BMT. Ideally, patients fair best who have mild to moderate GVHD without the toxicities of severe GVHD. [9] [10] [11] Given the potential benefit of GVHD, it is not unreasonable to ask why any prophylaxis is used in HLA matched sibling transplantation in the first place. The reason is that in the absence of prophylaxis, the incidence of 'hyperacute' acute GVHD approaches 100% and is associated with overwhelming morbidity. 12 Many strategies of GVHD prophylaxis have been explored, but the most common is the combination of CSP with MTX given on days 1, 3, 6, and 11 after allogeneic transplant.
1,2 The combination appears to be superior than either agent used alone. [13] [14] [15] A recent review from the EBMT showed that 93% of BMT centers used a combination of CSP and MTX for GVHD prophylaxis. 16 While the initial dose of CSP is relatively uniform, aiming to achieve therapeutic blood levels, the dose of MTX varies, with doses ranging from 5 to 15 mg/m 2 used. Some centers also use a different schedule, dosing on days þ 2, þ 4, þ 8, and potentially þ 12. 16 Finally, some centers utilize folinic acid rescue after MTX. 16 Unfortunately, the use of a cytotoxic agent such as MTX has the potential to result in delayed engraftment. 17, 18 Additionally, MTX is frequently accompanied by mucositis, which may be quite severe. 19, 20 As a result, some centers omit the day þ 11 dose of MTX. One center has reported that the omission of the day þ 11 dose did not result in any negative long-term sequelae, 20 but this report was contradicted by a subsequent report from another center. 21 MMF is a powerful immunosuppressive agent that inhibits the proliferation of T and B-lymphocytes. It has been used successfully to prevent and treat rejection in solid organ transplantation. 22, 23 Reports with limited patient numbers have shown efficacy of MMF, either alone or in combination with other agents, for GVHD prophylaxis as well as for the treatment of acute and chronic GVHD. [24] [25] [26] [27] Additionally, there appears to be synergism between MMF and CSP in preventing GVHD in dog models of transplantation. 28 This had led to the well-reported use of the combination of CSP and MMF for the prevention of graft rejection, as well as for the prophylaxis of GVHD in nonmyeloablative allogeneic transplants. [2] [3] [4] [5] [6] [7] In this setting, MMF is tolerated very well and this has allowed the nonmyeloablative transplant patients to frequently receive their care as outpatients.
The issue of mucositis in BMT is not trivial. It has been reported to contribute to a higher incidence of infection, and a longer inpatient length of stay in BMT patients. 29, 30 Increased regimen-related toxicity may be especially harmful to heavily pre-treated patients with refractory disease. Those patients frequently begin their transplants with periods of prior prolonged pancytopenia, and the added toxicity of mucositis induced by MTX may lead to serious clinical consequences. Thus, a GVHD prophylaxis regimen that reduces acute morbidities and achieves similar efficacy to CSP and MTX is noteworthy. In this prospective randomized trial we showed that patients receiving the combination of CSP and MMF had less severe mucositis, more rapid engraftment, and a shorter hospitalization, without an increased risk of infection. These clinically relevant results make the combination of CSP and MMF attractive in ablative transplants.
The primary limitation of this trial is the small sample size, and these results need to be verified in larger prospective randomized trials. Additionally, we used a busulfan-based preparative regimen, and it remains to be determined whether similar results would be achieved in patients receiving total body irradiation. We also did not use the most common dosage of MTX for GVHD prophylaxis. Most institutions use 15 mg/m 2 on day þ 1, followed by 10 mg/m 2 on days 3, 6, and 11; we used 5 mg/m 2 as described. This reduced dosage has been used at our institution, and others, for years, specifically designed to reduce the incidence and severity of mucositis associated with MTX. [31] [32] [33] However, confirming the results of this trial in patients treated with a more common MTX dosing regimen would be beneficial. Another potential problem with this trial is the fact that we used mucositis as a primary end point that resulted in premature study closure. As a result, the study is not powered to detect significant differences in overall survival. Additionally, the follow-up is relatively short, and cannot adequately address potential differences in chronic GVHD. Finally, all of our donors used bone marrow and not peripheral blood progenitor cells (PBPCs). More rapid engraftment seen with PBPCs has the potential to yield different results.
An effective GVHD regimen that leads to reduced mucositis, faster hematopoietic engraftment, and the ability to be used in patients with hepatic or renal impairment is desirable. Additional studies designed to determine the efficacy of CSP plus MMF in other populations of patients undergoing myeloablative allogeneic BMT are warranted.
